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Abstract
Background: 15-20% of all patients initially diagnosed with colorectal cancer develop metastatic disease and
surgical resection remains the only potentially curative treatment available. Current 5-year survival following R0-
resection of liver metastases is 28-39%, but recurrence eventually occurs in up to 70%. To date, adjuvant
chemotherapy has not improved clinical outcomes significantly. The primary objective of the ongoing LICC trial (L-
BLP25 In Colorectal Cancer) is to determine whether L-BLP25, an active cancer immunotherapy, extends
recurrence-free survival (RFS) time over placebo in colorectal cancer patients following R0/R1 resection of hepatic
metastases. L-BLP25 targets MUC1 glycoprotein, which is highly expressed in hepatic metastases from colorectal
cancer. In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in
patients with stage IIIB locoregional NSCLC.
Methods/Design: This is a multinational, phase II, multicenter, randomized, double-blind, placebo-controlled trial
with a sample size of 159 patients from 20 centers in 3 countries. Patients with stage IV colorectal adenocarcinoma
limited to liver metastases are included. Following curative-intent complete resection of the primary tumor and of
all synchronous/metachronous metastases, eligible patients are randomized 2:1 to receive either L-BLP25 or
placebo. Those allocated to L-BLP25 receive a single dose of 300 mg/m
2 cyclophosphamide (CP) 3 days before first
L-BLP25 dose, then primary treatment with s.c. L-BLP25 930 μg once weekly for 8 weeks, followed by s.c. L-BLP25
930 μg maintenance doses at 6-week (years 1&2) and 12-week (year 3) intervals unless recurrence occurs. In the
control arm, CP is replaced by saline solution and L-BLP25 by placebo. Primary endpoint is the comparison of
recurrence-free survival (RFS) time between groups. Secondary endpoints are overall survival (OS) time, safety,
tolerability, RFS/OS in MUC-1 positive cancers. Exploratory immune response analyses are planned. The primary
endpoint will be assessed in Q3 2016. Follow-up will end Q3 2017. Interim analyses are not planned.
Discussion: The design and implementation of such a vaccination study in colorectal cancer is feasible. The study
will provide recurrence-free and overall survival rates of groups in an unbiased fashion.
Trial Registration: EudraCT Number 2011-000218-20
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The primary objective of the ongoing LICC trial (L-
BLP25 In Colorectal Cancer) is to determine whether L-
BLP25, an active cancer immunotherapy, extends recur-
rence-free survival (RFS) time over placebo in colorectal
cancer pts following R0/R1 resection of hepatic metas-
tases. Stimuvax
® (BLP25 Liposome Vaccine or L-BLP25)
is an investigational therapeutic cancer vaccine co-devel-
oped by Oncothyreon Canada Inc. (formerly Biomira
Inc., Edmonton, Canada), and Merck KGaA, Darmstadt,
Germany for the use as an active specific immunother-
apy for MUC1- expressing tumors. Details of the physi-
cal, chemical and pharmaceutical properties, the non-
clinical trials and effects and safety in humans have
been published elsewhere 2008) [1].
Colorectal cancer is amongst the three most frequent
malignancies in Western countries [2,3]. Survival is deli-
neated by local recurrence, by lymphatic and predomi-
nantly by hematogenous dissemination [4]. Mutations in
tumor suppressor genes (APC, DCC, Smad-2, Smad-4,
p53) and oncogenes (K-ras) are molecular determinants
occurring during the development of sporadic colorectal
cancer, which was first summarized in the adenoma-car-
cinoma sequence described by Vogelstein et al. [5-7].
Since only 8% of colorectal cancers harbor concomitant
mutations of APC, K-ras, and p53, it seems very likely
that additional pathogenic alterations instrumentally
mediate progression and metastasis of colorectal cancer
[8].
At the time of first diagnosis, about 35% of colorectal
cancer patients have distant metastases [9]. Distant
metastases limited to the liver occur in 15-20% of all
patients initially diagnosed with colorectal cancer
[10-12]. However, only 15-20% of synchronic hepatic
metastases are resected by surgery. Complete surgical
resection of hepatic metastases represents the only cura-
tive option: cure is otherwise not attainable. The 5-year
survival after R0-resection of liver metastases ranges
between 28% to 39% [13,14]. Unfortunately, recurrence
rates after R0 resection of hepatic metastases peak at up
to 70% in the long-term follow-up [15].
The decision as to whether metastases are to be trea-
ted by surgical resection or by other therapeutic options
such as neoadjuvant chemotherapy, should be discussed
and determined by interdisciplinary tumor boards [9].
The requirements for surgical resections are (i) that
there is no evidence of extra-hepatic tumor, (ii) less
than 70% of the liver is tumor-bearing, (iii) fewer than 3
liver veins and fewer than 7 segments of the liver are
affected. Further exclusion criteria for surgical resection
of liver metastases are the presence of CHILD B/C cir-
rhosis and/or other severe concomitant diseases [16].
Using scoring systems such as that described by Fong,
the prognosis can be estimated preoperatively [17]. The
existence of at least two Fong points predicts a median
survival of 47 months after surgical resection of liver
metastasis. However, the Fong score is only an indirect
correlation of evaluated parameters (N-stage, size and
number of metastases, preoperative CEA value and
duration of disease-free interval) with the probability of
incidence of organ metastasis. Organ-bound micro-
metastases (MM) or disseminated tumor cells (DTC) are
considered precursors of metachronic solid liver metas-
tases [18-20].
A relevant clinical problem after primary or secondary
resection of hepatic metastases is the high recurrence
rate, ranging up to 70% [15]. According to de Jong and
colleagues, the median RFS after resection of liver
metastases is 23 months andthe median OS 36 months
[15]. The application of classical chemotherapeutic stra-
tegies has not been sufficiently successful. Adjuvant 5-
FU has non-significantly increased recurrence free survi-
val (RFS 1.6 yrs. vs. 2.3 yrs.; P = 0.06), however this did
not translate into a prolonged overall survival (4.0 vs.
5.0 years; P = 0.09) [21]. Similar data was published by
Portier et al., prolonging the 5-year-RFS (33.5% vs.
26.7%; P = 0.028) without augmenting the 5-year-survi-
val (51.1% vs. 41.1% P = 0.13) by an adjuvant 5-FU ther-
apy (EBM grade 2b) [22]. Parks et al. found that a 5-FU
based adjuvant chemotherapy versus watch and wait sig-
nificantly improved postoperative overall survival (P =
0.007); however these data were retrospectively analysed
registered data and thus not applicable (EBM grade 3b)
[23].
Nordlinger’s approach using peri-operative FOLFOX
non-significantly increased the 3-yrs RFS by 7.3% (28.1%
vs. 35.4%;P = 0.058); however patients treated per proto-
col (per protocol analysis) benefited even more (9.2%; 3-
yrs. RFS 33.2% vs. 42.2%; P = 0.025) (EBM grade 1b)
[24]. Other studies are limited by small numbers and do
not augment EBM grade 2b [25,26].
The German S3 Guideline recommends surgery of pri-
mary resectable liver metastases (recommendation grade
A; evidence grade 3b; strong consensus). In contrast, a
neoadjuvant chemotherapy of primary resectable metas-
tases is considered optional and is limited to well-
defined, exceptional cases (recommendation grade 0;
evidence grade 3, strong consensus). Postoperative adju-
vant chemotherapy after curative R0 resection of hepatic
metastases is considered optional ("can be considered";
recommendation grade B; evidence grade 2, strong con-
sensus) [9].
In contrast, according to the current consensus of the
“European colorectal metastases treatment group” use of
neoadjuvant/peri-operative combination chemotherapy
(e.g. FOLFOX) is suggested in the case of primary
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Page 2 of 9resectable liver metastases whereas for potentially
resectable liver metastases a neo-adjuvant combination
chemotherapy (e.g. FOLFOX or FOLFIRI) plus applica-
tion of a targeted therapy (bevacizumab, cetuximab,
panitumumab) should be considered. Isolated adjuvant
strategies are not recommended by the working group.
In summary, no generally accepted standard of care is
available following curative-intent resection of hepatic
metastases in colorectal cancer patients. L-BLP25 is a
therapeutic vaccine that targets MUC1, a well known
tumor-associated antigen. Recently, it has been shown
that MUC1 is associated with cellular transformation as
demonstrated by tumorigenicity [27] and can confer
resistance to genotoxic agents [28]. High levels of
MUC1 cell surface expression [29,30], reported immu-
nosuppressive activities of its released ectodomain [31]
and anti-adhesive properties [32,33] all contribute to the
ability of the MUC1 antigen to protect and promote
tumor cell growth and survival, making MUC1 an
attractive target for cancer immunotherapy.
Based on these results, L-BLP25 has a promising
potential as adjuvant therapy after curative-intent resec-
tion of hepatic metastases in colorectal cancer patients.
Methods/Design
Investigational medicinal product
L-BLP25 is a lyophilized preparation, formulated to con-
tain 241 μg of BLP25 lipopeptide and 128 μgo fi m m u -
noadjuvant monophosphoryl lipid A in a 5 mL glass
vial. The vial also contains 13,63 mg of liposomal lipids
consisting of dipalmitoyl phosphatidylcholine (DPPC),
cholesterol and dimyristoyl phosphatidylglycerol
(DMPG). The BLP25 lipopeptide and monophosphoryl
lipid A (MPL) are associated with the lipid bilayer of the
liposomes that are formed upon rehydration of the dry
powder (Figure 1). The active mechanism of L-BLP25 is
mediated by the entire liposome formed after reconsti-
tution. Only the entire liposomal formulation, in which
the antigen and adjuvant are integrated into the lipid bi-
layer, is capable of inducing the desired immune
response against MUC1. L-BLP25 was designed princi-
pally to induce a cellular immune response to tumor tis-
sues that express the MUC1 antigen. This cellular
response is characterized by the proliferation of CD4-
positive T cells in response to peptide, along with pro-
duction of gamma interferon and the generation of cyto-
toxic T lymphocytes (CTLs) capable of killing MUC1-
expressing tumor cells. The BLP25 lipopeptide provides
the antigenic specificity for the T cell response, while
the monophosphoryl lipid A serves as an adjuvant to
enhance the cellular immune responses. The liposomal
delivery system is designed to facilitate uptake of the
vaccine by antigen-presenting cells (APCs) delivering
the lipopeptide into the intracellular space, finally
leading to presentation of peptides via class I and class
II molecules of the HLA complex. This is expected to
elicit a MUC1-specific cellular immune response
mediated by T lymphocytes, including a CTL response.
Further information on the immunological background
supporting L-BLP25 and information on the immuniza-
tion schedule can be found in the Investigators Bro-
chure. Humoral responses to L-BLP25 are not expected,
based on the specific formulation of the vaccine, and
were found in only a few patients at low levels in pre-
vious clinical trials (EMR 63325-002, -003, and -004).
Additional file 1: Table S1 provides an outline of the
clinical trials conducted with L-BLP25 to date.
Trial objectives
Primary objective is the comparative evaluation of recur-
rence-free survival (RFS) time between the treatment
groups (L-BLP25 plus cyclophosphamide versus placebo
vaccination and saline infusion). Secondary objectives
are the comparative assessment of overall survival (OS)
time, safety/tolerability, recurrence-free survival time in
the subgroup of MUC1 positive cancers, and overall sur-
vival in the subgroup of MUC1 positive cancers. MUC1
expression analysis and immuno-monitoring parameters
are to be defined in separate translational protocol.
Trial design and plan
This is a randomized, placebo-controlled, multicenter,
double-blinded, efficacy/safety study of L-BLP25 in
patients with complete-resected metastatic CRC. Eligible
patients will have had their primary tumor resected and
have undergone curative-intent resection of liver
Figure 1 L-BLP25.
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Page 3 of 9metastases within the last 6 weeks. Eligible patients will
be randomized to treatment with L-BLP25 vaccine ver-
sus placebo (2:1). Treatment will be discontinued upon
documented relapse or, if subjects are free of relapse,
treatment will be discontinued 3 years after the first vac-
cination of the maintenance phase. Randomization of
159 subjects (106 to the investigational arm and 53 to
the control arm) was calculated. The enrollment period
is expected to run from Q3 2011 to Q3 2013. The sam-
ple size considerations are based on the following
assumptions:
￿ 2:1 randomization (106 pts. L-BLP25 vs. 53 pts.
placebo)
￿ Increase in relapse-free time from 18 months under
placebo to 24 months under L-BLP25 (i.e. a hazard ratio
of 0.75)
￿ Linearly increasing (cumulative) enrollment rate over
24 months
￿ 60 months of total trial duration (i.e., a minimum
follow-up of 36 months after the last patient included).
￿ a = 0.1 (1-sided) used for planning, which translates
to a 2-sided a-level of 20%
￿ Power 59%
￿ HR 0.75
￿ Lost to follow-up hazard rate 0.0027 (6% drop out
proportion at 60 months)
Follow-up will be event-driven and analysis is foreseen
after approximately 113 events (recurrences) are
reported unless this has still not occurred after comple-
tion of treatment of the last patient (i. e. 36 months
after randomisation of the last active patient, which is
approximately 60 months after initiation of the study).
Based on a median RFS time of 18 months in the con-
trol arm and linearly increasing (cumulative) enrollment
rate over 24 months, final analysis is projected at
approximately 60 months post trial initiation. Assuming
approximately 6% lost to follow-up, a total of 159 sub-
jects (106 subjects in the L-BLP25 arm and 53 subjects
in the control arm) will be enrolled to achieve the speci-
fied number of events in the scheduled follow-up time.
A Data Safety Monitoring Board (DSMB), monitoring
the trial periodically, will ensure continued subject safety
as well as the validity and scientific merit of the trial.
Diagnosis and main inclusion and exclusion criteria
This trial is designed for patients with metastatic color-
ectal carcinoma (CRC), who have undergone a complete
resection of their primary tumor and recent resection of
their liver metastases (R0 or R1) with curative intent.
E l i g i b i l i t yc r i t e r i af o rt h eL I C C - t r i a la r ed e p i c t e di n
Table 1 and 2.
Pre-treatment evaluations
After an informed consent form has been signed by the
subject, following evaluations will be undertaken within
28 days prior to the first administration of L-BLP25 or
placebo, and prior to the administration of cyclopho-
sphamide or saline solution: medical history, family his-
tory of autoimmune disease, vital signs, physical
examination (including height, weight and a limited
neurological examination), electrocardiogram (ECG),
ECOG performance status, imaging (computerized
tomography/magnetic resonance imaging (CT/MRI),
Table 1 Eligibility criteria for the LICC-trial
￿ Signed written informed consent.
￿ Male or female.
￿ At least 18 years of age.
￿ Female patients of childbearing potential (and if appropriate male patients with female partners of childbearing potential) must be willing to use
an adequate method of contraception for 4 weeks prior to, during and 12 weeks after the last dose of trial medication. A negative pregnancy test is
required for female subjects. Adequate contraception for female subjects is defined as two barrier methods, or one barrier method with a
spermicide, or intrauterine device or use of hormonal female contraceptive. For the purpose of this trial, women of childbearing potential are
defined as: “All female subjects after puberty unless they are post-menopausal for at least two years, are surgically sterile or are sexually inactive.”
￿ Histologically confirmed diagnosis of adenocarcinoma of the colon or rectum with complete resection of primary tumor and no evidence of local
relapse.
￿ Metastatic disease of the liver, with recent (< 6 weeks prior to randomization) resection (R0 or R1) of all liver metastases. Metastasectomy may have
been either synchronous or metachronous. Any neoadjuvant therapy may have been applied for maximal 3 months prior to metastasectomy.
￿ Subject has had a colonoscopy or rectoscopy within the last three months prior to initiation of therapy
￿ Subject has an ECOG performance status of 0 or 1.
￿ Subject has adequate hematologic, hepatic, and renal function within 2 weeks prior to initiation of therapy as defined by the following:
- Absolute neutrophils > 1,500/mm
3 and platelets > 140,000/mm
3.
- Bilirubin < 1.5 × upper limit of normal (ULN).
- AST and ALT < 2.5 × ULN.
- Creatinine < 1.5 × ULN.
- International Normalized Ratio (INR) and partial thromboplastin time (PTT) in the normal range of the local lab.
￿ Willingness to comply with study protocol requirements.
Inclusion criteria (Each of these to be met)
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test. Within 14 days prior to the first administration of
L-BLP25 or placebo and prior to administration of
cyclophosphamide or placebo, blood sampling for
hematology/serum biochemistry, coagulation, CEA,
CA19-9, ANA, SMA, SLA, LKM, AMA, ANCA, Anti-
HBc-IgG, Anti-HBc-IgM, Anti-HBs, HBs antigen and
anti-HCV will be performed (total blood volume for
Pre-treatment evaluations: 30 ml). A tumor sample (par-
affin fixed) must be available for immunohistochemical
MUC1 analysis. The MUC1 analysis will be carried out
in the central laboratory at Sponsor’s site, every other
standard laboratory analysis will be done in the local
laboratories.
Randomization
If the subject is deemed eligible, randomization will be
performed using a 2:1 ratio (Investigational arm: Placebo
arm) by the help of an IVRS.
Cyclophosphamide administration visit
Within 7 days of randomization and 3 days (72 hours ±
8 hours) prior to the first application of L-BLP25 or pla-
cebo, subjects will receive a single intravenous (I.V.)
infusion of a 300 mg/m
2 (maximum 600 mg) cyclopho-
sphamide (treatment arm) or a corresponding volume of
saline solution (control arm).
Primary treatment phase
Subjects will receive a target total 8 subcutaneous vacci-
nations of L-BLP25 or placebo at weekly intervals (pri-
mary treatment phase). Each vaccination consists of 4
subcutaneous injections. Injection sites will be inspected
30 minutes after injection.
The 5th visit of the vaccination schedule will addition-
ally include a physical examination, vital signs, ECOG
performance status, CEA, CA19-9, ANA, hematology/
serum biochemistry and coagulation.
A hepatic ultrasound will additionally be performed at
visit 8.
Evaluation after Primary Treatment Phase will take place
1 week after the completion of the primary treatment
phase (8
th vaccination). During this visit the following
tasks will be performed: physical examination, vital signs,
ECG, ECOG performance status, hematology/serum bio-
chemistry, coagulation, CEA, CA19-9 and ANA (total 30
ml blood volume), injection site inspection.
Maintenance treatment phase
Subjects will receive vaccinations at 6-week intervals
during year 1 and 2, commencing 6 weeks after the end
of the primary treatment phase. Vaccination intervals
will be 12 weeks in year 3. Subjects will receive vaccina-
tions until documentation of recurrence or the patient
Table 2 Eligibility criteria for the LICC-trial
￿ Metastases other than liver metastases.
￿ R2 and Rx resected liver metastases. Patients with R1 resected liver metastases can be included if a further surgical resection is seen as not
indicated or necessary in the surgeon’s opinion.
￿ Chemotherapy within 4 weeks prior to randomization.
￿ Receipt of immunotherapy (e.g. interferons, tumor necrosis factor, interleukins, or growth factors [GM-CSF, G-CSF, M- CSF], monoclonal antibodies)
within 4 weeks (28 days) prior to randomization.
￿ Any known autoimmune disease, past or current.
￿ A recognized immunodeficiency disease including cellular immuno-deficiencies, hypogammaglobulinemia or dysgammaglobulinemia; hereditary or
congenital immunodeficiencies.
￿ Known or newly diagnosed active hepatitis B infection and/or hepatitis C infection, autoimmune hepatitis, known human immunodeficiency virus
infection, or any other infectious process that in the opinion of the investigator could compromise the subject’s ability to mount an immune
response, or expose him/her to likelihood of more and/or severe side effects.
￿ Past or current history of malignant neoplasm other than CRC, except for curatively treated non-melanoma skin cancer, in-situ carcinoma of the
cervix or other cancer curatively treated and with no evidence of disease for at least 5 years.
￿ Medical or psychiatric conditions that would interfere with ability to provide informed consent, communicate side effects, or comply with protocol
requirements.
￿ Clinically significant cardiac disease, e.g. cardiac failure of New York Heart Association classes III-IV; uncontrolled angina pectoris, uncontrolled
arrhythmia, uncontrolled hypertension, myocardial infarction in the previous 12 months as confirmed by an ECG.
￿ Splenectomy.
￿ Previous (less than 4 weeks prior to randomization) or concurrent treatment with a non-permitted drug.
￿ Pregnancy and lactation period.
￿ Participation in another clinical study within 30 days prior to randomization.
￿ Known hypersensitivity to the study treatment drugs.
￿ Known alcohol or drug abuse.
￿ Legal incapacity or limited legal capacity.
￿ Any other reason that, in the opinion of the investigator, precludes the patient from participating in this study.
Exclusion criteria
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years after the first vaccination of the maintenance
treatment phase. Vital signs will be taken and injection
sites will be inspected 30 minutes after vaccination. In
addition, starting with the end of the primary treatment
phase, a physical examination, ECOG performance sta-
tus, CEA, CA19-9, ANA, hematology/serum biochemis-
try, coagulation (total 30 ml blood volume per
assessment) and a serum or urine pregnancy test
(women of childbearing potential only) will be per-
formed every 12 weeks, plus additional sampling for
hematology/biochemistry only every intermediate 6
weeks until after week 92 (total blood volume 12 ml per
assessment). Vaccination intervals will be 6 weeks dur-
ing years 1 and 2 after first vaccination and 12 weeks
during year 3 after first vaccination.
End of treatment evaluation
When recurrence has been documented or the subject is
discontinued, study treatment is to be discontinued. 12
weeks after the last treatment, an End of Treatment
Evaluation will be performed, consisting of vital signs,
physical examination, ECOG performance status, hema-
tology/serum biochemistry,c o a g u l a t i o n ,E C G ,C E A ,
CA19-9, ANA (total 30 ml blood volume), serum or
urine pregnancy test (women of childbearing potential
only), CT/MRI, hepatic ultrasound and injection site
inspection. When second-line treatment is indicated,
and initiation is planned less than 12 weeks after the
last treatment, then the end of treatment evaluation will
be performed prior to the intitation of second-line
therapy.
Long term follow-up
After the last treatment, i.e. after documented relapse or
after the subject or investigator has decided to stop
treatment, the investigator or his/her designee will con-
tact the subject every 6 months for documentation of
recurrence status and survival status. The follow-up for
all patients ends 4 years after the last active patient in
the maintenance treatment phase has received the first
dose of the maintenance therapy (i.e. had had two such
follow-up assessments). All SAEs persisting at the end
of the study will be followed up until resolved/stabilized
or an alternative cause is found. At the first long term
follow-up 6 months after last treatment general autoim-
mune phenomena will be queried.
Safety assessment and concomitant treatment
AE assessment and recording of concomitant medica-
tion and concurrent procedures will be done during all
visits in both treatment phases. During long term fol-
low-up, AEs which are considered to be related to the
investigational product will be recorded.
Lab assessments and total blood volume collected
Standard laboratory assessments include serum bio-
chemistry, hematology, coagulation, CEA, CA19-9 and
ANA. Prior to first treatment additionally to the stan-
dard laboratory assessment ANA, SMA, SLA, LKM,
AMA, ANCA, AntiHBc-IgG, Anti-HBc-IgM, anti-HBs,
HBs antigen and anti-HCV are to determined. A
planned maximum of 564 ml blood will be drawn dur-
ing the clinical trial; in the case of AE monitoring
additional blood samples may be drawn. Respectively,
30 ml per assessment will be drawn for the pre-treat-
ment evaluation, at week 5 of the primary treatment
phase, 1 week after the primary treatment phase, at 12
different time points during the maintenance treatment
phase (weeks 14, 26, 38, 50, 62, 74, 86, 98, 110, 122,
134 and 146) and at the end of treatment evaluation.
During the maintenance phase, additional 12 ml sam-
pling per assessment for biochemistry and hematology
only will be drawn at weeks 20, 32, 44, 56, 68, 80 and
92. All routine lab assessments including labeling will
be performed in the local laboratories according to the
local standard and local range. An additional 100 ml
blood per assessment will be drawn for the transla-
tional program in weeks 9, 26, 50, and 98 in order to
evaluate the immune responses (cellular/humoral) to
the vaccine/placebo. A total blood volume of 500 ml
will be drawn for the translational program. Analytical
test, parameters, labeling, shipment and technique of
analyses for blood samples used for the translational
program will be described in the separate translational
program.
Imaging
CT or MRI imaging of the chest and abdomen alter-
nating with US imaging of the liver for recurrence will
b ep e r f o r m e de v e r y6w e e k si ny e a r s1a n d2s t a r t i n g
after the end of primary treatment phase, e.g. US after
8 weeks, CT after 14 weeks, US after 20 weeks. In year
3, CT or MRI imaging and alternating US imaging for
relapse will be performed every 12 weeks. At study
treatment termination CT/MRI and US imaging will
be performed. CT/MRI will be performed according to
local standard. Images will be evaluated according to
Response Evaluation Criteria in Solid Tumors (RECIST
1.1) guidelines in order to guarantee uniformity. A
maximum of 12 CT/MRI scans will be performed: at
the pretreatment evaluations, following CT scans at
weeks 14, 26, 38, 50, 62, 74, 86, 98, 122 and 146 and
at the end of treatment evaluation (12 weeks after last
treatment). Subjects who stop treatment prior to docu-
mentation of relapses will be required to undergo
appropriate CT/MRI evaluation for detection of
relapse. Subjects who withdraw from the study for
clinical or symptomatic deterioration before objective
documentation of relapse will be required to undergo
appropriate CT/MRI to confirm relapse. Every reason-
able effort will be made to ensure recurrence is
confirmed.
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The recurrence risk after curatively intended resection
of hepatic metastases in CRC patients ranges up to 70%
[15]. No generally accepted adjuvant or perioperative
strategies are available, significantly reducing the recur-
rence rate or prolonging overall survival [9]. According
to the German S3 guideline, adjuvant chemotherapy
after R0 resection of liver metastases can be considered,
whereas neo-adjuvant chemotherapy prior to resection
of liver metastases can be considered in reasonable
exceptional cases [9]. In contrast, R0 resectable metas-
tases limited to the liver should be resected. In sum-
mary, the recommendation for neoadjuvant/adjuvant
chemotherapy is currently not strong in Germany. As
the majority of centers is located in Germany we
decided to comply with the German guidelines, knowing
that peri-operative chemotherapy is considered standard
of care in some other countries.
Participating centers confirmed the acceptance of the
protocol containing a placebo arm. The standard treat-
ment of care after resection of liver metastases in the
participating centers is to watch and wait. As a conse-
qunce, the study offers a potentially effective verum
treatment to two thirds of participating patients, which
would not receive any treatment otherwise.
In addition, we accept patients treated in a neoadju-
vant manner, if the neoadjuvant therapy has lasted 12
weeks or less. This is necessary, as some patients have
been treated in a neoadjuvant setting, but the patients
are presented for the study only post surgery. As a short
chemotherapy does not interfere with the postoperative
immune system capacity, we agreed to include those
patients. A significant impact of neoadjuvant che-
motherapy has not been proven so far. Thus, the ethics
committee and the Paul-Ehrlich-Institute accepted
inclusion criteria.
CRC is reported to have MUC1 expression in ~61% of
pT1, 78% of pT2, 98% of pT3 and 90% of pT4 colorectal
cancer samples and thus clearly correlates with invasive-
ness, being an optimal target for MUC1 based vaccina-
tion strategies after resection of hepatic metastases [34].
In addition, MUC1 expression was found in 100% (56/
56) of colorectal cancer liver metastases [35]. A MUC1
expression of > 85% is expected in the study population
analyzed, as the vast majority of metastatic cases will be
pT3/pT4. It has been well discussed, that an
Figure 2 Study design.
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Page 7 of 9engagement of the immune system might be the most
successful therapeutic option to reduce micro-metas-
tases and thus decreased recurrence rates and increase
recurrence free survival time and overall survival time
[36,37].
L-BLP25 is designed to induce cellular cytotoxicity
towards MUC1 expressing tumor cells. Doses of 1,000
μg have increased overall survival time in NSCLC
patients from 13.3 months to 30.0 months in patients
with stage IIIB disease without pleural effusion (HR
0.55) [38,39]. A similar effect would be highly beneficial
for patients after hepatic metastasectomy who have a
high recurrence risk (70%) with a median time to recur-
rence of ~18-23 months [15,21].
Thus, we aim to test L-BLP-25 vaccine in a rando-
mized, placebo-controlled, multicenter, double blinded,
safety/efficacy study in patients with metastatic CRC. Eli-
gible patients will have had their primary tumor resected
and will have undergone curative-intent resection of liver
metastases (R0/R1) within the last 6 weeks. Since the per-
centage of colorectal cancers expressing MUC1 is very
high, MUC1 testing results are not required prior to
inclusion. Further, the significance of detection of MUC1
expression in a tumor sample is unclear, due to the fact
that this may not mean that the tumor is truly negative
for MUC1, patients whose tumors are not shown to be
expressing MUC1 can be included into this study. Eligi-
ble patients will be randomized via IVRS to treatment
with L-BLP-25 versus placebo (2:1). Treatment will be
discontinued upon documented relapse or if subjects are
free from relapse, treatment will be discontinued 3 years
after first application.
The dose regimen and treatment schedule will be the
same as those used in Trial EMR 63325-001 (worldwide
phase III, START). Throughout the development of L-
BLP25, a single low-dose of cyclophosphamide (300 mg/
m
2 to a maximum of 600 mg) has been administered
prior to initiation of treatment with L-BLP25. The pur-
pose is to overcome the immune suppression seen in
cancer subjects and thus to enhance the development of
an effective immune response to the MUC1 immunogen
present in the vaccine.
We also decided to accept patients treated in a neo-
adjuvant manner, if the neoadjuvant therapy has lasted
12 weeks or less. This became necessary, as some
patients have been treated in a neo-adjuvant setting,
but are presented for the study evaluation only post
surgery. As a short chemotherapy seems not interfere
with the postoperative immune system capacity, we
agreed to include those patients in order to optimize
accrual.
Patients in the investigational arm receive cyclopho-
sphamide prior to immunotherapy, in an attempt to
overcome the immune suppression seen in cancer
subjects. Therefore, to maintain the double-blind design,
subjects in the control arm will receive saline solution
i nt h es a m ec a l c u l a t e dd o s ev o l u m ea st h a to f
cyclophosphamide.
The design and implementation of the current vacci-
nation study in colorectal cancer is feasible. The study
will provide recurrence-free and overall survival rates of
groups in an unbiased fashion.
Additional material
Additional file 1: Table S1 L-BLP25 Clinical Trials.
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